Brenda Chan
About Brenda Chan
Brenda Chan is a Senior Research Associate at ORIC Pharmaceuticals Inc., where she focuses on researching resistant cancer mechanisms and treatment strategies. She holds both a Bachelor of Science and a Master of Science in Biochemistry from the University of California, Los Angeles.
Work at ORIC Pharmaceuticals
Brenda Chan has been employed at ORIC Pharmaceuticals Inc. since 2019. She started as a Research Associate II and transitioned to the role of Senior Research Associate in 2021. In her current position, she focuses on researching resistant cancer mechanisms and treatment strategies. Her work contributes to the company's mission of developing innovative therapies for cancer patients.
Education and Expertise
Brenda Chan earned her Master of Science in Biochemistry from the University of California, Los Angeles (UCLA), completing her studies from 2014 to 2018. She graduated with both a Bachelor of Science and a Master of Science in Biochemistry in September 2018. Her academic background includes significant research experience, which enhances her expertise in biochemistry and cancer research.
Background
During her time at UCLA, Brenda Chan conducted various research projects. She investigated aging processes through studies on drosophila, which provided insights into genetic and environmental factors affecting aging. Additionally, she explored the effects of ellagic acid on diet-induced insulin resistance, contributing to the understanding of metabolic health.
Research Experience
Brenda Chan's research experience includes conducting studies on biofuels using anaerobic bacteria during her undergraduate studies. This foundational research experience has informed her current work in cancer research, where she applies her knowledge of biochemical processes to understand and develop treatment strategies for resistant cancer mechanisms.